Prognostic factors for overall survival and safety of DEBIRI TACE in patients with colorectal liver metastases

Authors

  • Peter Popovič
  • Maja Šljivič
  • Maša Sever
  • Janja Ocvirk
  • Tanja Mesti
  • Erik Brecelj

Abstract

Background:

Transarterial chemoembolisation with irinotecan-loaded drug-eluting beads (DEBIRI TACE) can be considered in patients with unresectable colorectal cancer liver metastases (CRLM) who progress after all approved standard therapies or in patients unsuitable for systemic therapy.

Patients and methods:

Between September 2010 and March 2020, thirty patients (22 men and 8 women; mean age 66,8 ± 13,2) were included in this retrospective study. DEBIRI TACE was conducted in 43 % of patients unsuitable for systemic therapy as a first-line treatment and 57 % as salvage therapy after the progression of systemic therapy. All the patients had liver-limited disease. In the case of unilobar disease, two treatments were performed at four-week intervals, and in the case of bilobar disease, four treatments were performed at two-week intervals. All patients were premedicated and monitored after the procedure. Adverse events were graded according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) classification system for complications.

Results:

The median OS from the beginning of DEBIRI TACE in the salvage group was 17,4 months; in the group without prior systemic therapy, it was 21,6 months. The median overall survival of all patients was 17,4 months (95 % CI: 10,0–24,7 months), and progression-free survival was 4,2 months (95 % CI: 0,9–7,4 months). The one-year survival rate after the procedure was 61 %, and the two-year rate was 25 %. Univariate analysis showed better survival of patients with four or fewer liver metastases (p = 0,002). There were no treatment-related deaths or grade 4 and 5 adverse events. Nonserious adverse events (grades 1 and 2) were present in 53% of patients, and grade 3 adverse events were present in 6% of the patients.

Conclusions:

DEBIRI TACE is a well-tolerated treatment option for patients with liver metastases of colorectal cancer. Patients with four or fewer liver metastases correlated with better survival.

 

Keywords: colorectal cancer, liver metastases, irinotecan, drug-eluting beads, transarterial chemoembolisation, survival

Author Biographies

Maja Šljivič

1 Faculty of Medicine Ljubljana, Ljubljana, Slovenia 

2 Clinical Institute of Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

Maša Sever

3 Faculty of Medicine Belgrade, Serbia 

Janja Ocvirk

1 Faculty of Medicine Ljubljana, Ljubljana, Slovenia 

4 Institute of Oncology, Ljubljana, Slovenia 

University of Primorska, Faculty of Health Sciences, Slovenia 

 

Tanja Mesti

1 Faculty of Medicine Ljubljana, Ljubljana, Slovenia 

4 Institute of Oncology, Ljubljana, Slovenia 

 

 

Erik Brecelj

1 Faculty of Medicine Ljubljana, Ljubljana, Slovenia 

4 Institute of Oncology, Ljubljana, Slovenia 

 

 

Downloads

Published

2024-06-10

How to Cite

Popovič, P., Šljivič, M., Sever, M., Ocvirk, J., Mesti, T., & Brecelj, E. (2024). Prognostic factors for overall survival and safety of DEBIRI TACE in patients with colorectal liver metastases. Radiology and Oncology, 58(2), 214–220. Retrieved from https://www.radioloncol.com/index.php/ro/article/view/4340

Issue

Section

Clinical oncology